TIDMAMYT
Amryt Pharma PLC
31 March 2021
Amryt Supports World Lipodystrophy Day - March 31, 2021
DUBLIN, Ireland, and Boston MA, March 31, 2021, Amryt (Nasdaq:
AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical
company focussed on acquiring, developing and commercializing novel
treatments for rare diseases , is pleased to announce its support
for World Lipodystrophy Day 2021 which will take place today.
Lipodystrophy is a debilitating ultra-rare disease characterized
by the lack of subcutaneous fat. The inability to store fat under
the skin causes fat to be stored in places such as the muscles and
liver which leads to severe metabolic complications including
insulin resistance, diabetes, dyslipidemia, heart disease, kidney
disease, fatty liver disease and many others. Currently, there is
no cure for lipodystrophy and only the secondary complications can
be managed/treated. Lipodystrophy affects approximately 1 in 1
million people across the world.
Amryt Pharma would like to join the global lipodystrophy patient
community to raise awareness and highlight the burden and impact of
this profoundly distressing condition on lipodystrophy
patients.
Dr Joe Wiley, CEO of Amryt Pharma, commented today: "
Lipodystrophy is a complex and extremely rare disease that affects
approximately 1 person in every 1 million. People and families with
lipodystrophy face an enormous challenge as it can take many years
of worsening, distressing symptoms before they get a correct
diagnosis and treatment. Education and awareness are critical to
improve this diagnostic odyssey and to improve the lives of people
living with lipodystrophy. We are delighted to support the global
lipodystrophy patient community today on World Lipodystrophy
Day."
About Amryt
Amryt is a global commercial-stage biopharmaceutical company
focused on acquiring, developing and commercializing innovative
treatments to help improve the lives of patients with rare and
orphan diseases. Amryt comprises a strong and growing portfolio of
commercial and development assets.
Amryt's commercial business comprises two orphan disease
products - metreleptin (Myalept(R)/ Myalepta(R)) and lomitapide (
Juxtapid(R)/ Lojuxta(R)).
Myalept(R) / Myalepta(R) (metreleptin) is approved in the US
(under the trade name Myalept(R)) as an adjunct to diet as
replacement therapy to treat the complications of leptin deficiency
in patients with congenital or acquired generalized lipodystrophy
(GL) and in the EU (under the trade name Myalepta(R)) as an adjunct
to diet for the treatment of leptin deficiency in patients with
congenital or acquired GL in adults and children two years of age
and above and familial or acquired partial lipodystrophy (PL) in
adults and children 12 years of age and above for whom standard
treatments have failed to achieve adequate metabolic control. For
additional information, please follow this link .
Juxtapid(R)/ Lojuxta(R) (lomitapide) is approved as an adjunct
to a low-fat diet and other lipid-lowering medicinal products for
adults with the rare cholesterol disorder, Homozygous Familial
Hypercholesterolaemia ("HoFH") in the US, Canada, Columbia,
Argentina and Japan (under the trade name Juxtapid(R)) and in the
EU, Israel and Brazil (under the trade name Lojuxta(R)). For
additional information, please follow this link .
Amryt's lead development candidate, Filsuvez (R) (Oleogel-S10)
is a potential treatment for the cutaneous manifestations of
Junctional and Dystrophic Epidermolysis Bullosa ("EB"), a rare and
distressing genetic skin disorder affecting young children and
adults for which there is currently no approved treatment.
Filsuvez(R) has been selected as the brand name for Oleogel-S10.
The product does not currently have regulatory approval to treat
EB.
Amryt's pre-clinical gene therapy platform, AP103, offers a
potential treatment for patients with Dystrophic EB, and is also
potentially relevant to other genetic disorders.
For more information on Amryt, including products, please visit
www.amrytpharma.com .
The person making this notification on behalf of Amryt is Rory
Nealon, CFO/COO and Company Secretary.
Financial Advisors
Shore Capital ( Edward Mansfield, Daniel Bush, John More) are
NOMAD and Joint Broker to Amryt in the UK. Stifel (Ben Maddison)
are Joint Broker to the company in the UK.
Forward-Looking Statements
This press release may contain forward-looking statements
containing the words "expect", "anticipate", "intends", "plan",
"estimate", "aim", "forecast", "project" and similar expressions
(or their negative) identify certain of these forward-looking
statements. The forward-looking statements in this announcement are
based on numerous assumptions and Amryt's present and future
business strategies and the environment in which Amryt expects to
operate in the future. Forward-looking statements involve inherent
known and unknown risks, uncertainties and contingencies because
they relate to events and depend on circumstances that may or may
not occur in the future and may cause the actual results,
performance or achievements to be materially different from those
expressed or implied by such forward-looking statements. These
statements are not guarantees of future performance or the ability
to identify and consummate investments. Many of these risks and
uncertainties relate to factors that are beyond each of Amryt's
ability to control or estimate precisely, such as future market
conditions, the course of the COVID-19 pandemic, currency
fluctuations, the behaviour of other market participants, the
outcome of clinical trials, the actions of regulators and other
factors such as Amryt's ability to obtain financing, changes in the
political, social and regulatory framework in which Amryt operates
or in economic, technological or consumer trends or conditions.
Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or
implied, is made regarding future performance. No person is under
any obligation to update or keep current the information contained
in this announcement or to provide the recipient of it with access
to any additional relevant information that may arise in connection
with it. Such forward-looking statements reflect the Company's
current beliefs and assumptions and are based on information
currently available to management.
Contacts
Joe Wiley, CEO / Rory Nealon, CFO/COO, +353 (1) 518 0200,
ir@amrytpharma.com
Edward Mansfield, Shore Capital, NOMAD, +44 (0) 207 468 7906,
edward.mansfield@shorecap.co.uk
Tim McCarthy, LifeSci Advisors, LLC, +1 (212) 915 2564,
tim@lifesciadvisors.com
Amber Fennell, Consilium Strategic Communications, +44 (0) 203
709 5700, fennell@consilium-comms.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFLFERVLIIVIL
(END) Dow Jones Newswires
March 31, 2021 06:00 ET (10:00 GMT)
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Amryt Pharma (LSE:AMYT)
Historical Stock Chart
From Mar 2023 to Mar 2024